Reproductive and Developmental Biology

The Korean Society of Animal Reproduction (한국동물번식학회)
권호 표지

Inhibition of Histone Deacetylase Activity Diminishes Pressure Overloaded Cardiac Hypertrophy in Mice

  • Hong, Yun-Kyung (Department Rehabilitation Science in Interdisciplinary PhD Program, Graduate School of Inje University) ;
  • Song, Jong-Wook (Cardiovascular and Metabolic Disease Center, College of Biomedical Science and Engineering) ;
  • Lee, Sang-Kil (Cardiovascular and Metabolic Disease Center, College of Biomedical Science and Engineering) ;
  • Lee, Young-Jeon (Department Rehabilitation Science in Interdisciplinary PhD Program, Graduate School of Inje University) ;
  • Rho, Gyu-Jin (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Kim, Joo-Heon (Institute of Animal Medicine, College of Veterinary Medicine, Gyeongsang National University) ;
  • Hong, Yong-Geun (Department Rehabilitation Science in Interdisciplinary PhD Program, Graduate School of Inje University)
  • Received : 2011.05.28
  • Accepted : 2011.06.20
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

To explore the role of histone deactylase (HDAC) activation in an in vivo model of hypertrophy, we studied the effects of Trichostatin A (TSA). TSA subjected to thoracic aortic banding (TAB)-induced pressure stress in mice. In histological observations, TAB in treated mice showed a significant hypertrophic response, whereas the sham operation remained nearly normal structure with partially blunted hypertrophy. TSA treatment had no effect (measured as HW/BW) on sham-operated animals. TAB animals treated with vehicle manifested a robust ~50% hypertrophic response (p<0.05 vs sham). TAB mice treated with 2 mg/kg/day TSA manifested a blunted growth responses, which was significantly diminished (p<0.05) compared with vehicle-treated TAB mice. TAB mice treated with a lower dose of TSA (0.5 mg/kg/day) manifested a similar blunting of hypertrophic growth (~25% increase in heart mass). Furthermore, to determine activity duration of TSA in vitro, 1 nM TSA was added to H9c2 cells. Histone acetylation was initiated at 4 hr after treatment, and it was peak up to 18 hr, then followed by significantly reduced to 30 hr. We also analyzed the expression of p53 following TSA treatment, wherein p53 expression was elevated at 4 hr, and it was maintained to 24 hr after treatment. ERK was activated at 8 hr, and maintained till 30 hr after treatment suggesting an intracellular signaling interaction between TSA and p53 expression Taken together, it is suggested that HDAC activation is required for pressure-overload growth of the heart. Eventually, these data suggest that histone acetylation may be a novel target for therapeutic intervention in pressure-overloaded cardiac hypertrophy.

Keywords

References

  1. Braunwald E (2001): Heart Disease: a Textbook of Cardiovascular Medicine. Ch. 13. W.B. Saunders Philadelpia.
  2. Brown DW, Giles WH, Croft JB (2000): Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 140:848-856. https://doi.org/10.1067/mhj.2000.111112
  3. Department of Health, Education, and Welfare, Public Health Service (1979): Proceeding of the Conference on the Decline in Coronary Heart Disease Mortality. U.S. USA, pp 79-1610.
  4. Department of Health and Human Services, Public Health Service (1988): The Surgeon General's Report on Nutrition and Health, 1988. U.S. USA, pp 88-50210.
  5. Department of Health and Human Services, Public Health Services (1989): Health, United States, 1990. U,S. National Center for Health Statistics. USA, pp 89-1232.
  6. Department of Health and Human Services, Public Health Services (2002): Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. USA, pp 89-2925.
  7. Epstein ND, Davis JS (2003): Sensing stretch is fundamental. Cell 112:147-150. https://doi.org/10.1016/S0092-8674(03)00037-0
  8. Frey N, McKinsey TA, Olson EN (2000): Decoding calcium signals involved in cardiac growth and function. Nat Med 6:1221-1227. https://doi.org/10.1038/81321
  9. Frey N, Katus HA, Olson EN, Hill JA (2004): Hypertrophy of the heart: a new therapeutic target? Circulation 109:1580-1589. https://doi.org/10.1161/01.CIR.0000120390.68287.BB
  10. Goldman L, Cook EF (1984): The decline in ischemic heart disease mortality rates: An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 101:825-836. https://doi.org/10.7326/0003-4819-101-6-825
  11. Gordon T, Garcia-Palmieri MR, Kagan A, Kannel WB, Schiffman J (1974): Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chronic Dis 27:329-344. https://doi.org/10.1016/0021-9681(74)90013-7
  12. Gusterson RJ, Jazrawi E, Adcock IM, Latchman DS (2003): The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem 278:6838-6847. https://doi.org/10.1074/jbc.M211762200
  13. Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, Weiss RM, Kutschke W, Bassel-Duby R, Williams RS (2002): Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J Biol Chem 277:10251-10255. https://doi.org/10.1074/jbc.M110722200
  14. Imai S, Armstrong CM, Kaeberlein M, Guarente L (2000): Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403:795-800. https://doi.org/10.1038/35001622
  15. Jenuwein T, Allis CD (2001): Translating the histone code. Science 293:1074-1080. https://doi.org/10.1126/science.1063127
  16. Johnson CA, Turner BM (1999): Histone deacetylases: complex transducers of nuclear Signals. Semin Cell Dev Biol 10:179-188. https://doi.org/10.1006/scdb.1999.0299
  17. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (1984): The 1984 Report of the joint national committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 144:1045-1057. https://doi.org/10.1001/archinte.1984.00350170211032
  18. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, Hill JA (2006): Suppression of class I and II histone deacetylases blunts pressure-over-load cardiac hypertrophy. Circulation 113:2579-2588. https://doi.org/10.1161/CIRCULATIONAHA.106.625467
  19. Kook H, Lepore JJ, Gitler AD, Lu MM, Wing-Man Yung W, Mackay J, Zhou R, Ferrari V, Gruber P, Epstein JA (2003): Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 112:863-871. https://doi.org/10.1172/JCI19137
  20. Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, Wolffe AP, Nakatani Y, Roeder RG, Cole PA (2006): HATs off: Selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 5:589-595.
  21. Lu J, McKinsey TA, Nicol RL, Olson EN (2000): Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA 97:4070-4075. https://doi.org/10.1073/pnas.080064097
  22. Marks AR (2003): Calcium and heart : A question of life and death. J Clin Invest 111:597-600. https://doi.org/10.1172/JCI18067
  23. McKinsey TA, Olson EN (1999): Cardiac hypertrophy : Sorting out the circuitry. Curr Opin Genet Dev 9:267-274. https://doi.org/10.1016/S0959-437X(99)80040-9
  24. Molkentin JD (2000): Calcineurin and beyond : Cardiac hypertrophic signaling. Circ Res 87:731-738. https://doi.org/10.1161/01.RES.87.9.731
  25. Nabauer M, Kaab S (1998): Potassium channel down-regulation in heart failure. Cardiovasc Res 37:324-334. https://doi.org/10.1016/S0008-6363(97)00274-5
  26. Nuss HB, Kaab S, Kass DA, Tomaselli GF, Marban E (1999): Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am J Physiol 277:80-91.
  27. Olson EN, Schneider MD (2003): Sizing up the heart: development redux in disease. Genes Dev 17:1937-1956. https://doi.org/10.1101/gad.1110103
  28. Pan LN, Lu J, Huang BQ (2007): HDAC inhibitors: A potential new category of anti-tumor agents. Cell Mol Immunol 4:337-343.
  29. Seidman JG, Seidman C (2001): The genetic basis for cardiomyopathy : From mutation identification to mechanistic paradigm. Cell 104:557-567. https://doi.org/10.1016/S0092-8674(01)00242-2
  30. Tomaselli GF, Marban E (1999): Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42:270-283. https://doi.org/10.1016/S0008-6363(99)00017-6
  31. Wang Z, Kutschke W, Richardson KE, Karimi M, Hill JA (2001): Electrical remodeling in pressure-overload cardiac hypertrophy: role of calcineurin. Circulation 104:1657-1663. https://doi.org/10.1161/hc3901.095766
  32. Wang Z, Nolan B, Kutschke W, Hill JA (2001): $Na^+-CA^{2+}$ exchanger remodeling in pressure overload cardiac hypertrophy. J Biol Chem 276:17706-17711. https://doi.org/10.1074/jbc.M100544200
  33. Wickenden AD, Kaprielian R, Kassiri Z, Tsoporis JN, Tsushima R, Fishman GI, Backx PH (1998): The role of action potential prolongation and altered intracellular calcium handling in the pathogenesis of heart failure. Cardiovasc Res 37:312-323. https://doi.org/10.1016/S0008-6363(97)00256-3
  34. World Health Organization: World Health Statistics Annual 1970-1990. International vital statistics and population data in tabular form by country.
  35. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, New-some D, Bronson RT, Li E, Livingston DM, Eckner R (1998): Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93:361-372. https://doi.org/10.1016/S0092-8674(00)81165-4
  36. Zhang CL, McKinsey TA, Chang S, Antos CL, Hill JA, Olson EN (2002): Class II histone deacetylase act as signal-responsive repressors of cardiac hypertrophy. Cell 110:479-488. https://doi.org/10.1016/S0092-8674(02)00861-9